Market Place
Sourcing Support
NanoViricides Inks MSA for NV-387 Orphan Drug Designation
01 Dec 2025 //
PHARMIWEB
Nanoviricides Strengthens Fiscal Position With Subsequent Raise
17 Nov 2025 //
PHARMIWEB
Nanoviricides To Present NV-387 Efficacy Against H3N2 at Summit
14 Nov 2025 //
PHARMIWEB
Nanoviricides Completes $6M Direct Offering & Private Placement
12 Nov 2025 //
PHARMIWEB
Nanoviricides Prices $6M Direct Offering And Private Placement
11 Nov 2025 //
PHARMIWEB
Nanoviricides Begins Phase II Trial Of NV-387 For Mpox In Congo
10 Nov 2025 //
PHARMIWEB
Nanoviricides Annual Shareholders Meeting Set For November 8
05 Nov 2025 //
PHARMIWEB
Nanoviricides To Present at Spartan Capital Investor Conference
03 Nov 2025 //
PHARMIWEB
Nanoviricides CEO Dr. Anil Diwan Interviewed On Measles
29 Oct 2025 //
PHARMIWEB
Nanoviricides To Present At PODD 2025 Conference In Boston
27 Oct 2025 //
PHARMIWEB
Nanoviricides Reports Nv-387`s Strong Antiviral Activity
22 Oct 2025 //
PHARMIWEB
NanoViricides NV-387 Shows Potent, Safe Activity Against Measles
20 Oct 2025 //
PHARMIWEB
Nanoviricides` Dual Clinical Strategy: NV-387 In Phase II Trials
15 Oct 2025 //
PHARMIWEB
Nanoviricides Has Filed Its Annual Report
30 Sep 2025 //
PHARMAWEB
NanoViricides to Present at LSX Congress, Boston, Sept 17, 2025
11 Sep 2025 //
ACCESSWIRE
NanoViricides to Speak at LSX Congress, Boston, September 17
09 Sep 2025 //
ACCESSWIRE
NanoViricides: NV-387 May Treat Flu, RSV, Covid, Mpox, Measles
23 Jul 2025 //
ACCESSWIRE
WHO Extends MPox Alert, NanoViricides` NV-387 in Focus
16 Jul 2025 //
ACCESSWIRE
NanoViricides Nears Completion of MPox Clade I Trial Design
14 Jul 2025 //
ACCESSWIRE
NanoViricides Measles Drug Development Animal Study is Imminent
04 Jun 2025 //
ACCESSWIRE
NanoViricides CEO Says FDA COVID Vaccine Policy Long Overdue
22 May 2025 //
ACCESSWIRE
NanoViricides Updates on NV-387, Targets MPox, Measles, Flu
16 May 2025 //
ACCESSWIRE
Antiviral Drug NV-387 Approved for Phase II Trial in Congo
08 May 2025 //
ACCESSWIRE
NanoViricides Says Stock Decline Misguided, Won’t Affect Growth
11 Mar 2025 //
ACCESSWIRE
NanoViricides, Inc. Has Filed its Quarterly Report
19 Feb 2025 //
ACCESSWIRE
NanoViricides to Present at MicroCap Conference on Jan 29
29 Jan 2025 //
ACCESSWIRE
NanoViricides Engages CRO for Phase II Clinical Trial
28 Jan 2025 //
ACCESSWIRE
NanoViricides to Present at Showcase in San Fransisco on Jan
13 Jan 2025 //
ACCESSWIRE
Multiple Viral Threats Call for Preparedness with Antivirals
08 Jan 2025 //
ACCESSWIRE
NanoViricides Poised to Fight Bird Flu with H5N1 Drug
23 Dec 2024 //
ACCESSWIRE
NanoViricides Advances NV-387 to Ph 2 for MPOX, RSV, Influenza
15 Nov 2024 //
ACCESSWIRE
NanoViricides President Dr. Diwan to Present at the PODD Conference
22 Oct 2024 //
ACCESSWIRE
NanoViricides President Dr. Diwan Interviwed in PODD Podcast
15 Oct 2024 //
ACCESSWIRE
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
08 Oct 2024 //
ACCESSWIRE
NanoViricides Files Annual Report: NV-387 Progressing To Ph 2
30 Sep 2024 //
ACCESSWIRE
NanoViricides Investigates MEURI Protocol For NV-387 To Treat MPOX
26 Aug 2024 //
ACCESSWIRE
NanoViricides Progresses Towards Phase II Trial Of NV-387 Antiviral
19 Aug 2024 //
ACCESSWIRE
NanoViricides Updates On NV-387 Clinical Program And Strategy
08 Aug 2024 //
ACCESSWIRE
Two Reports Highlight NanoViricides` Potential In Viral Therapy
01 Aug 2024 //
ACCESSWIRE
NanoViricides Plans Next Phase For Multi-Respiratory Virus Drug Trials
11 Jul 2024 //
ACCESSWIRE
NanoViricides Positioned With Clinical, Pre-Clinical Pipeline, Virus-Kill Tech
01 Jul 2024 //
ACCESSWIRE
NV-387 Broad-Spectrum Antiviral Could Combat Bird Flu H5N1, Says NanoViricides
24 Jun 2024 //
ACCESSWIRE
NV-387 Antiviral Protects Lungs In Lethal Influenza A Animal Model
20 Jun 2024 //
ACCESSWIRE
NV-387 Shows Ideal Blood Profile For Sustained Antiviral Effect
12 Jun 2024 //
ACCESSWIRE
NV-387: Sustained Release Enables Infrequent Dosing For Antivirals
04 Jun 2024 //
ACCESSWIRE
Broad Antiviral For RSV COVID Flu Other Viruses In Development
29 May 2024 //
ACCESSWIRE
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
23 May 2024 //
ACCESSWIRE
Oral NV-387 Shows Normal Lung Histology In Lethal RSV
20 May 2024 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 May 2024 //
ACCESSWIRE
NanoViricides At EF Hutton Conference In NYC On May 15
10 May 2024 //
ACCESSWIRE
Novel Broad-Spectrum Antiviral Active Against Smallpox/Mpox
08 May 2024 //
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
06 May 2024 //
ACCESSWIRE
NanoViricides: Phase I NV-387 Trial Completed, Data Lock Soon
30 Apr 2024 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 Feb 2024 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 Nov 2023 //
ACCESSWIRE
NanoViricides Announces thatTrials of Its Broad-Spectrum Antiviral Drug NV-CoV-2
29 Jun 2023 //
ACCESSWIRE
NanoViricides, Inc. to Present at the BIO International Convention
31 May 2023 //
ACCESSWIRE
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference
04 May 2023 //
GLOBENEWSWIRE
NanoViricides is Expanding its Broad-Spectrum Antiviral Program
25 Apr 2023 //
ACCESSWIRE
NanoViricides Signs Agreement for Evaluation of COVID-19 Drug Candidates
04 Apr 2023 //
ACCESSWIRE
